Thank you for the thought-provoking message, Mr. Kinnunen. 
Here are a couple of questions, if you have time to answer them sometime, that would be great. Thank you in advance for your responses!
-
How are Revenio’s new products, such as the renewed Maia microperimeter and the iCare ILLUME screening solution, expected to impact the company’s market position and earnings growth in the coming years? What are the key competitive advantages of these products?
-
Could you elaborate on the risks associated with Revenio’s FDA approval process in the United States and how these risks might affect the company’s earnings development? How has the company prepared for potential delays or failures in the approval process?